Volume 104, Issue 9 pp. 2727-2746
REVIEW

In Vitro Blood–Brain Barrier Models—An Overview of Established Models and New Microfluidic Approaches

Anette Wolff

Corresponding Author

Anette Wolff

Lund University, Department of Biomedical Engineering, Lund, Sweden

Telephone: +46-709948974; Fax: +46-46222 4527; E-mail: [email protected]Search for more papers by this author
Maria Antfolk

Maria Antfolk

Lund University, Department of Biomedical Engineering, Lund, Sweden

Search for more papers by this author
Birger Brodin

Birger Brodin

University of Copenhagen, Department of Pharmacy, Copenhagen, Denmark

Search for more papers by this author
Maria Tenje

Maria Tenje

Lund University, Department of Biomedical Engineering, Lund, Sweden

Uppsala University, Department of Engineering Sciences, Uppsala, Sweden

Search for more papers by this author
First published: 28 January 2015
Citations: 25

Abstract

The societal need for new central nervous system (CNS) medicines is substantial, because of the global increase in life expectancy and the accompanying increase in age-related CNS diseases. Low blood–brain barrier (BBB) permeability has been one of the major causes of failure for new CNS drug candidates. There has therefore been a great interest in cell models, which mimic BBB permeation properties. In this review, we present an overview of the performance of monocultured, cocultured, and triple-cultured primary cells and immortalized cell lines, including key parameters such as transendothelial electrical resistance values, permeabilities of paracellular flux markers, and expression of BBB-specific marker proteins. Microfluidic systems are gaining ground as a new automated technical platform for cell culture and systematic analysis. The performance of these systems was compared with current state-of-the-art models and it was noted that, although they show great promise, these systems have not yet reached beyond the proof-of-concept stage. In general, it was found that there were large variations in experimental protocols, BBB phenotype markers, and paracellular flux markers used. It is the author's opinion that the field may benefit greatly from developing standardized methodologies and initiating collaborative efforts on optimizing culture protocols. © 2015 Wiley Periodicals, Inc. and the American Pharmacists Association J Pharm Sci 104:2727–2746, 2015

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.